Anti-Microbial Peptides Market: Potential Chronic Diseases Drug And Alternatives For Antibiotics

By Goldstein Market Intelligence || 2018-02-03 2:35:42 AM

Anti-Microbial Peptides Market: Potential Chronic Diseases Drug And Alternatives For Antibiotics

According to Goldstein Research, “Medical industry is struggling to provide better cure for deadly and unknown origin diseases. Thrive for effective drugs are attracting the pharmaceutical industry to opt for advanced technologies. Anti-microbial peptides acts directly on microbial pathogens and have potential to fight against the unexpected rise of resistant organisms. Anti-microbial peptides are expected to have an attractive market as new antibiotics in therapeutics in the near future.

“Global Anti Microbial Peptides Market Outlook 2024”

Global anti-microbial peptides market is segmented on the basis of peptides types such as plant anti-microbial peptides, bacterial anti-microbial peptides, animal anti-microbial peptides, insect anti-microbial peptides. Among these segments, animal and plant anti-microbial peptides are capturing the major share into the market as they are easy to extract as compared with other anti-microbial peptides. Researchers are also more inclined towards animal and plant anti-microbial peptides to observe and check under clinical trials.

Europe and North America are the leading regions in global anti-microbial peptide market owing to the large investment in R&D and healthcare industry. Europe anti-microbial peptides market valued USD 0.39 billion in 2016, and is projected to grow at a CAGR of 9.0% during the forecast period. There are approximately 45 peptides which are approved globally and are being used in different verticals out of which 5-6 are from Europe. European Union has announced to invest USD 1.7 billion to develop antimicrobial peptide drugs to tackle against drug-resistant bacteria. Europe was marketed for nearly 110 peptides in clinical trials and more than 150 peptides in advanced pre-clinical phase. Germany and the UK hold the major share of antimicrobial peptides market. Moreover, Greece is the largest and only producer of generic peptides of European Union.

 Potential drug for cancer treatment

Anti-microbial peptides are able to disintegrate deadly cancerous cell membranes and thus considered as a future drug for the treatment of cancer. Clinical trials are being performed to develop an effective drug for cancer treatment as it has shown potential to restrict the growth of cancer cells. Anti-microbial peptide also has an ability to act against sexually transmitted diseases and HIV/HPV which is anticipated to witness a huge demand in the near future.

“Global Anti Microbial Peptides Market outlook 2024” contains detailed overview of the global anti-microbial peptides market in terms of market segmentation by peptides type, by product and by application.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.

Global anti-microbial peptides market also provides competitive outlook of some of the major players of global anti-microbial peptides market which includes profiling of companies such as AnaSpec Inc., Chinese Peptides, Novozymes, Lonza, Ipsen, Bachem Holding AG, Nuritas, Dermagen, Phoenix Biotech, AMP Biotech, Shanghai Abbiochem Company, Ramamoorthy Group, Lytix Biopharma AS, Ai2 Ltd and C3 Jian Therapeutics. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.

Overall, the report represents comprehensive synopsis on the global anti-microbial peptides market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Send Us Sample Request

Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.

Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.